A Phase 2 Trial of Everolimus and Pasireotide Long Acting Release in Patients with Metastatic Uveal Melanoma

OBJECTIVES: Test the hypothesis that inhibiting mammalian target of rapamycin (mTOR) and Insulin Growth Factor-1 Receptor would be efficacious in metastatic uveal melanoma. METHODS: Phase 2 trial of everolimus 10mg daily plus pasireotide long-acting release 60mg every 28 days enrolling patients with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Melanoma Res
Autores principales: Shoushtari, Alexander N., Ong, Leonard T., Schoder, Heiko, Singh-Kandah, Shahnaz, Abbate, Kelly, Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd, Chapman, Paul B., Panageas, Katherine S., Schwartz, Gary K., Carvajal, Richard D.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553199/
https://ncbi.nlm.nih.gov/pubmed/26795274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000234
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares